CSL Limited is a biotherapeutics company that develops and delivers biotherapies. The Company's principal activities are research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. Its segments include CSL Behring, Seqirus and CSL Intellectual Property. The CSL Behring segment manufactures, markets and develops plasma therapies (plasma products and recombinants). The Seqirus segment manufactures and distributes non-plasma biotherapeutic products. Seqirus manufactures, sells and distributes a range of vaccines, antivenoms and other pharmaceutical products in Australia and New Zealand. It also manufactures and markets in vitro diagnostic products through Seqirus immunohematology. The CSL Intellectual Property segment is engaged in licensing of intellectual property generated by the Company to unrelated third parties. The Company has facilities in Australia, Germany, Switzerland, the United Kingdom and the United States.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: ASX:CSL
- CUSIP: N/A
- Web: www.csl.com.au/
Average Prices:- 50 Day Moving Avg: A$128.55
- 200 Day Moving Avg: A$128.50
P/E:- Trailing P/E Ratio: 45.40
- P/E Growth: 0.00
Dividend:
Profitability:- Net Margins: 16.35%
- Return on Equity: 34.95%
- Return on Assets: 12.30%
Frequently Asked Questions for CSL Limited (ASX:CSL)
What is CSL Limited's stock symbol?
CSL Limited trades on the ASX under the ticker symbol "CSL."
Who are some of CSL Limited's key competitors?
Some companies that are related to CSL Limited include Grifols, S.A. (GRFS), Jazz Pharmaceuticals PLC (JAZZ), ProMetic Life Sciences (PLI), Theratechnologies (TH), Mirati Therapeutics (MRTX), SIGA Technologies (SIGA), Osiris Therapeutics (OSIR), Anavex Life Sciences Corp. (AVXL), XOMA (XOMA), VBI Vaccines (VBIV), Concordia International Corp (CXR), Protalix Biotherapeutics (PLX), ContraFect Corporation (CFRX), Trillium Therapeutics (TRIL), Aevi Genomic Medicine (GNMX), Ohr Pharmaceuticals (OHRP), Can Fite Biopharma Ltd (CANF) and Can Fite Biopharma Ltd (CANF).
Who are CSL Limited's key executives?
CSL Limited's management team includes the folowing people:
- Paul Perreault, Chief Executive Officer, Managing Director, Executive Director
- David Mark Lamont, Chief Financial Officer
- Gordon Naylor, President - Seqirus
- Greg Boss, Executive Vice President, Legal and CSL Group General Counsel
- Karen Etchberger, Executive Vice President - Quality and Business Services
- Bob Repella, Executive Vice President - Global Commercial Operations
- Val Romberg, Executive Vice President of Manufacturing and Planning
- Alan J. Wills, Senior Vice President - Strategy and Business Development
- Andrew Cuthbertson, Chief Scientific Officer, R&D Director
- Laurie Cowan, Senior Vice President - Human Resources
MarketBeat Community Rating for CSL Limited (ASX CSL)MarketBeat's community ratings are surveys of what our community members think about CSL Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for CSL Limited (ASX:CSL) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for CSL Limited (ASX:CSL)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for CSL Limited (ASX:CSL)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for CSL Limited (ASX:CSL)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for CSL Limited (ASX:CSL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for CSL Limited (ASX:CSL)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for CSL Limited (ASX:CSL)
Latest Headlines for CSL Limited (ASX:CSL)
| Source: |
|
| Date | Headline |
|---|
 | Why the Starpharma Holdings Limited share price rocketed higher ... - Motley Fool Australia
www.fool.com.au - September 22 at 9:40 PM |
| Is the CSL Limited share price about to storm higher?
www.fool.com.au - September 19 at 10:37 PM |
 | CSL Behring Will Help Transform Biotech Education and Research with $4.92 Million Gift to Penn State
finance.yahoo.com - September 19 at 5:35 PM |
 | Seqirus Donates Influenza Vaccine for Hurricane Harvey Relief in Texas - Business Wire (press release)
www.businesswire.com - September 15 at 11:04 PM |
 | CSL Behring Joins Together With Conference Attendees to Make Donation to IPOPI - PR Newswire (press release)
www.prnewswire.com - September 15 at 11:04 PM |
| CSL Behring Announces FDA Approval of Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] for the ... - PR Newswire (press release)
www.prnewswire.com - September 15 at 11:04 PM |
 | FDA approves CSL Behring drug for third use
www.bizjournals.com - September 15 at 6:01 PM |
| Why the Mayne Pharma Group Ltd share price is climbing higher
www.fool.com.au - September 14 at 11:26 PM |
| CSL Behring Announces FDA Approval of Privigen® for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults
finance.yahoo.com - September 14 at 11:26 PM |
| CSL Behring Joins Together With Conference Attendees to Make Donation to IPOPI
finance.yahoo.com - September 14 at 6:25 PM |
| Seqirus Receives FDA Approval of AFLURIA QUADRIVALENT® (Influenza Vaccine) for People Five Years of Age and Older in the U.S.
finance.yahoo.com - September 14 at 6:25 PM |
| Seqirus Donates Influenza Vaccine for Hurricane Harvey Relief in Texas
finance.yahoo.com - September 13 at 6:52 PM |
| Canadian Parents Willing to Vaccinate Their Infants with Adjuvanted Influenza Vaccine, Study Finds
finance.yahoo.com - September 11 at 6:12 PM |
| New Phase III Study Shows Significantly Greater Efficacy in Children 6-24 Months Who Receive Adjuvanted Influenza Vaccine (aQIV)
finance.yahoo.com - September 11 at 6:12 PM |
| Can expensive CSL Limited shares deliver capital growth in FY18?
www.fool.com.au - September 5 at 7:10 PM |
| CSL Ltd. breached its 50 day moving average in a Bullish Manner : CSL-AU : September 5, 2017
finance.yahoo.com - September 5 at 3:31 AM |
| 3 small-cap shares with strong growth potential - Motley Fool Australia
www.fool.com.au - September 4 at 10:28 PM |
| Hidden beneath the flat ASX stock market is a whole other world of opportunity - Motley Fool Australia
www.fool.com.au - September 4 at 3:11 AM |
| 2 top healthcare companies I'm watching like a hawk - Motley Fool Australia
www.fool.com.au - September 3 at 10:08 PM |
| ETFs with exposure to CSL Ltd. : August 29, 2017
finance.yahoo.com - August 29 at 10:58 PM |
| $91M deal: CSL acquires stem cell gene therapy developer
www.bizjournals.com - August 28 at 5:24 PM |
| CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform
finance.yahoo.com - August 28 at 5:24 PM |
| [$$] CSL Behring to Buy Biotech Startup Calimmune for $416 Million
finance.yahoo.com - August 28 at 5:24 PM |
| Is CSL Limited buying its way to growth? - Motley Fool Australia
www.fool.com.au - August 27 at 9:58 PM |
| Why the Mayne Pharma Group Ltd share price fell 7% today | Motley ... - Motley Fool Australia
www.fool.com.au - August 25 at 3:51 AM |
| CSL Ltd. :CSL-AU: Earnings Analysis: 2017 By the Numbers : August 22, 2017
finance.yahoo.com - August 22 at 11:11 PM |
| CSL Ltd. :CSL-AU: Earnings Analysis: For the six months ended June 30, 2017 : August 23, 2017
finance.yahoo.com - August 22 at 11:11 PM |
 | CSL Limited Leader In High Growth Plasma Sales To China
seekingalpha.com - August 22 at 6:10 PM |
 | Australia shares end lower as caution prevails; NZ slightly down
www.reuters.com - August 21 at 4:50 AM |
| Australia shares fall on weaker financials, global cautious; NZ also down
www.reuters.com - August 20 at 11:48 PM |
| Why the Primary Health Care Limited share price has sunk lower today - Motley Fool Australia
www.fool.com.au - August 18 at 4:52 AM |
| Are CSL Limited shares a buy after yesterday’s profit result?
www.fool.com.au - August 17 at 4:01 AM |
| Edited Transcript of CSL.AX earnings conference call or presentation 16-Aug-17 1:00am GMT
finance.yahoo.com - August 16 at 5:59 PM |
 | CSL FY Profit Rises
www.rttnews.com - August 15 at 11:18 PM |
| CSL Limited -- Moody's takes rating action on CSL Limited
finance.yahoo.com - August 15 at 6:18 PM |
| Berinert® Approved by Health Canada for the Treatment of Hereditary Angioedema (HAE) in Pediatric Patients
finance.yahoo.com - August 9 at 5:45 PM |
| Seqirus Announces Major Advances in Pandemic Preparedness ... - Business Wire (press release)
www.businesswire.com - August 8 at 4:00 AM |
| Mayne Pharma Group Ltd shares sink on trading update - Motley Fool Australia
www.fool.com.au - August 8 at 4:00 AM |
| Xencor's (XNCR) CEO Bassil Dahiyat on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 7 at 10:58 PM |
| Seqirus Announces Major Advances in Pandemic Preparedness
finance.yahoo.com - August 7 at 5:58 PM |
| Think about this if you want to own shares forever - Motley Fool Australia
www.fool.com.au - August 4 at 12:00 AM |
| Global Markets for Blood Plasma Products
www.bizjournals.com - August 1 at 6:14 PM |
| Global Hereditary Angioedema Market: Industry Analysis & Outlook (2017-2021) - Upcoming Novel Drugs to Drive ... - Business Wire (press release)
www.businesswire.com - July 31 at 10:31 PM |
| Global Market for Blood Plasma Was Worth $16.8 Billion in 2016 - Expected to Reach $23.0 Billion in 2021
www.bizjournals.com - July 29 at 4:54 PM |
| 2 ASX shares for a falling Aussie dollar - Motley Fool Australia
www.fool.com.au - July 28 at 7:25 PM |
| HAEGARDA® (C1 Esterase Inhibitor Subcutaneous ) Now Available in the United States for Patients with Hereditary Angioedema
finance.yahoo.com - July 25 at 5:33 PM |
| Here's what has happened to the Australian Dollar (A$) - Motley Fool Australia
www.fool.com.au - July 24 at 10:19 PM |
| ETFs with exposure to CSL Ltd. : July 24, 2017
finance.yahoo.com - July 24 at 5:17 PM |
| 3 Things In Biotech You Should Learn Today: July 22, 2017
seekingalpha.com - July 23 at 5:14 PM |
| CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) - PR Newswire (press release)
www.prnewswire.com - July 22 at 5:21 AM |
